The FDA did not respond to a request for comment. U.S. Health Secretary Robert F. Kennedy Jr. has said that the agency's ...

A former critic of FDA and Pharma will now oversee the regulation of costly and complicated biologics like vaccines, gene therapies, and blood supply.

Michael Rogers, a top official at the Food and Drug Administration, announced Monday he is retiring amid the Trump ...

changes in FDA leadership; and (3) plans to reorganize the Agency and reduce its workforce. On March 25, 2025, Martin "Marty" Makary was confirmed by the Senate to be the 27th Commissioner of Food ...

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

His answer marks a change from during the Biden ... vaccines official from the FDA. Former FDA officials have criticized the agency's new political leadership for their intervention in vaccine ...

an oncologist who has previously criticized FDA leadership and COVID-19 mandates, as the director of its Center for Biologics Evaluation and Research (CBER), the agency said on May 6.

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...

Amid a slew of recent shake-ups at the FDA—including the agency’s reduction in force and high-profile leadership exits—the regulator is ushering in "radical" changes to how it signs off on ...

Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry ...